United Therapeutics Corporation
UTHR
Positions held
Your positionsUTHR isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- United Therapeutics operates in a niche market with a strong focus on innovative therapies for pulmonary arterial hypertension, reducing competition risk.
- In Q2 2026, the company reported a revenue of $783.3 million, maintaining a gross margin of 87.3%.
- The operating margin for Q2 2026 was 42.2%, demonstrating consistent profitability.
- The company's revenue growth is currently negative at -1.9%, indicating potential challenges in market demand.
- For the year 2025, United Therapeutics reported a revenue of $3.182 billion, which is lower than the previous year's growth rate.
- The trailing P/E ratio stands at 19.4, suggesting that the stock may be overvalued compared to its earnings growth.
Fundamentals
| Market cap | $22.85B | Enterprise value | $20.19B | Trailing P/E | 19.08 | Forward P/E | 15.77 |
| PEG | 2.22 | Price / book | 3.55 | Beta | 0.49 | Dividend yield | 0.00% |
| Revenue growth | -1.9% | Earnings growth | 13.4% | Gross margin | 86.1% | Operating margin | 42.2% |
| Profit margin | 41.6% | ROE | 19.3% | ROA | 11.6% | Debt / equity | — |
| Current ratio | 5.73 | Free cash flow | $557.14M | Analyst recommendation | buy | Mean target | $651.86 |
| 52w high | $609.35 | 52w low | $409.07 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $783M | $782M | $790M | $800M | $799M |
| Op margin | 42.2% | 41.7% | 45.2% | 48.7% | 48.4% |
| Net income | $333M | $275M | $364M | $339M | $310M |
| Gross margin | 87.3% | 82.9% | 86.9% | 87.4% | 89.0% |
| Gross profit | $684M | $648M | $687M | $699M | $711M |
| Operating income | $331M | $326M | $358M | $389M | $386M |
- Revenue +0% vs prior quarter ($783M vs $782M).
- Gross margin 87.3% (was 82.9% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.2B | $2.9B | $2.3B | $1.9B | — |
| Op margin | 47.7% | 50.3% | 50.9% | 50.6% | — |
| Net income | $1.3B | $1.2B | $985M | $727M | — |
| Gross margin | 87.9% | 89.2% | 88.9% | 92.2% | — |
| Gross profit | $2.8B | $2.6B | $2.1B | $1.8B | — |
| Operating income | $1.5B | $1.4B | $1.2B | $980M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · United Therapeutics Insider Sold Shares Worth $5,215,015, According to a Recent SEC Filing
2026-10-08 · RBC Raises Price Target on United Therapeutics to $708 From $677, Keeps Outperform Rating
2026-10-07 · 3 Reasons to Avoid UTHR and 1 Stock to Buy Instead
2026-10-07 · Liquidia (LQDA) Could Be 74% Undervalued As Court Ruling Clouds YUTREPIA Access
2026-10-06 · United Therapeutics Insider Sold Shares Worth $5,145,537, According to a Recent SEC Filing
2026-10-05 · United Therapeutics Insider Sold Shares Worth $5,219,015, According to a Recent SEC Filing
2026-10-01 · United Therapeutics Insider Sold Shares Worth $3,926,177, According to a Recent SEC Filing
2026-10-01 · United Therapeutics Insider Sold Shares Worth $1,056,425, According to a Recent SEC Filing
2026-10-01 · United Therapeutics Just Sent Liquidia Stock Lower After Patent Battle
2026-10-01 · Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
2026-10-01 · Liquidia Shares Drop After Downgrades From Raymond James, BTIG
Price (daily)
Full chart · RSI · MACD · patterns